Anixa Biosciences Inc

NASDAQ ANIX

Download Data

Anixa Biosciences Inc Average Collection Period 2 year CAGR for the year ending October 31, 2023: -16.82%

Anixa Biosciences Inc Average Collection Period 2 year CAGR is -16.82% for the year ending October 31, 2023, a 82.88% change year over year. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Anixa Biosciences Inc Average Collection Period for the year ending October 31, 2022 was 0.04.
  • Anixa Biosciences Inc Average Collection Period for the year ending October 31, 2019 was 1,899.09, a 1,366.38% change year over year.
NASDAQ: ANIX

Anixa Biosciences Inc

CEO Dr. Amit Kumar Ph.D.
IPO Date Jan. 1, 1987
Location United States
Headquarters 3150 Almaden Expressway, San Jose, CA, United States, 95118
Employees 4
Sector Healthcare
Industry Biotechnology
Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Similar companies

CUE

Cue Biopharma

NA

NA

INMB

INmune Bio Inc

NA

NA

ANVS

Annovis Bio Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email